In this video, health-care analyst David Williamson discusses Eli Lilly and its surprising accomplishment of hitting a new 52-week high despite poor trial results for Alzheimer's drug solanezumab. What is propelling shares forward? Watch and find out along with David's take on the recent developments.

Profiting from our increasingly global economy can be as easy as investing in your own backyard. Our free report "3 American Companies Set to Dominate the World" shows you how. Click here to get your free copy before it's gone.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.